Celularity Inc (CELUW)

Celularity Inc is a biotechnology company that manufactures and develops cell therapies derived from human placental tissue. The company’s core business sits squarely in the supply chain of regenerative medicine: it sources placental material upstream (a renewable, non-controversial tissue source), manufactures standardised cell populations in its own facility, and supplies both its own clinical programs and contract manufacturing services to other therapeutic developers downstream. This supply-chain position — controlling raw material, manufacturing capacity, and product development in-house — is what distinguishes Celularity from many rivals who license technology from academia or depend on external manufacturers.

Origin and the tissue supply advantage

Celularity emerged from Cord Blood Registry (now owned by Cryo-Cell), a company that had pioneered the collection and cryopreservation of cord blood and tissue. That foundation shaped Celularity’s defining characteristic: access to a ready, renewable supply of placental material. While competitors relying on bone marrow, adipose tissue, or donor recruitment must navigate constrained sourcing or ethical friction, Celularity’s model begins with a byproduct available at every birth — a tissue stream that exists nowhere else in the current cell-therapy landscape. The company licensed that tissue-access right and built its own manufacturing operation on top of it.

The company began clinically testing its lead product, a natural killer cell therapy, in 2019. Natural killer cells are a class of immune cell that recognises and kills cancerous and infected cells without requiring engineering — unlike CAR T therapies, which must be laboriously manufactured for each patient, placental-derived NK cells can be manufactured in bulk and used off-the-shelf across many patients. This off-the-shelf advantage is fundamental to Celularity’s positioning: lower cost per patient, faster manufacturing, and no need for patient-specific genetic manipulation.

The portfolio: two business streams

Proprietary therapies. Celularity’s own pipeline includes programs in myeloma, lymphoma, glioblastoma, and infectious diseases such as COVID-19 complications and cytomegalovirus. Most remain in early clinical stages. The company generates no meaningful product revenue from these; they exist as proof-of-concept for the cell types and manufacturing process, and as long-term commercial opportunities if clinical data supports approval.

Contract manufacturing. Beginning in 2024 and accelerating into 2025, Celularity has entered agreements to manufacture cell therapies for other companies. In February 2025, it signed a collaboration with BlueSphere Bio to produce TCR T-cell therapies at Celularity’s facility in Florham Park — a contract that covers chemistry, manufacturing, quality assurance, and quality control. This stream is strategically important: it converts the company’s excess manufacturing capacity into near-term revenue and validates the scalability and quality of its processes to the broader cell-therapy industry.

The supply-chain economics and manufacturing moat

Cell therapy manufacturing is capital-intensive and technically complex. Celularity’s advantage is not technological uniqueness — many companies can manufacture NK cells or CAR T cells if they have the right equipment and expertise — but rather the combination of reliable tissue sourcing and a purpose-built, cGMP-certified facility. Building and certifying a manufacturing plant can take years and cost tens of millions. For companies developing therapies, outsourcing manufacturing to an established, regulated facility is faster and cheaper than building their own.

The economics work in Celularity’s favour as the cell-therapy market matures. Today, most therapies are in early clinical stages, so manufacturing demand is thin. Over the next five to ten years, as approved therapies enter the market and clinical programs advance, manufacturing capacity becomes a bottleneck. Celularity’s decision to open its facility to contract work before it has a blockbuster of its own is a bet that it will capture that capacity premium before new competitors build their own plants.

This positioning is also supply-chain resilience. Cell therapies are manufactured fresh and have limited shelf life. Patients in Europe, Asia, or other regions benefit from distributed manufacturing rather than shipping from a single site. Contract manufacturing agreements, if they grow, could fund expansion to additional facilities.

Revenue and trajectory

The company reported net sales of $54.2 million in 2024, up from $22.8 million in 2023 — a 138 percent increase driven by contract manufacturing. This is still a very early-stage revenue base; for context, most biopharmaceutical companies at this stage of pipeline development carry minimal revenue. Celularity’s revenue growth is noteworthy because it shows the contract business is scaling.

The company is not profitable. It is burning cash on research and development for its proprietary pipeline, ongoing clinical trials, and facility operations. Most of its cash has come from an initial public offering and subsequent capital raises. Without a marketed product of its own, Celularity depends on continued access to capital and on its contract-manufacturing revenue to extend cash runway.

Risks and pressures

Clinical risk. Most of Celularity’s pipeline remains in early clinical trials. Cell therapies have suffered setbacks in the market (several high-profile CAR T programs disappointed patients and safety, despite regulatory approval). There is no guarantee Celularity’s therapies will work or be approved.

Competition. The cell-therapy field is crowded. Larger, well-funded companies (Gilead, Bluebird, 2Seventy Bio) have approved or advancing CAR T therapies. Multiple competitors source placental or cord-blood derived cells. Celularity’s tissue advantage is real but not insurmountable; others can attempt to build similar sourcing agreements or tissue banks.

Capital intensity. Building and running a manufacturing facility costs money. Expanding to new geographies or capacities requires more capital. If the company cannot raise funding, it will slow spending, defer expansion, or merge.

Contract dependency. The company’s near-term survival now depends partly on securing and retaining manufacturing contracts. These can be won, but they can also be lost to competitors or internalised by customers who build their own capacity.

How to research Celularity

Start with the company’s most recent 10-Q filing (SEC CIK 0001752828), which breaks down contract manufacturing revenue, cash burn, and clinical-trial progress. Watch quarterly earnings calls for updates on contract wins or losses, clinical-trial patient enrollment, and cash-burn rate. Compare Celularity’s gross margins on contract work to those of other contract manufacturers in biotech; that ratio will signal whether the business model is economically durable.

Keep an eye on the broader cell-therapy market: when therapies in the market suffer safety setbacks, it can slow patient enrolment in experimental trials and reduce investor appetite for funding. Conversely, successful approvals validate the cell-type and expand the total addressable market for manufacturing. Celularity’s fortunes are tied tightly to whether placental-derived or engineering-modified cell therapies prove effective over the medium term.